WO2013093629A3 - Modular vaccines, methods and compositions related thereto - Google Patents
Modular vaccines, methods and compositions related thereto Download PDFInfo
- Publication number
- WO2013093629A3 WO2013093629A3 PCT/IB2012/003006 IB2012003006W WO2013093629A3 WO 2013093629 A3 WO2013093629 A3 WO 2013093629A3 IB 2012003006 W IB2012003006 W IB 2012003006W WO 2013093629 A3 WO2013093629 A3 WO 2013093629A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- vaccines
- treatment
- compositions related
- modular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
The invention relates to the field of methods and related compositions for the preparation and administration of vaccines, such as DNA vaccines, for the treatment of one or more diseases. In other embodiments, the invention relates to the field of methods for the prevention or treatment of disease comprising administration of one or more vaccines, such as DNA vaccines, for the treatment of a disease to a patient in need thereof. In a particular embodiment, the invention provides a DNA vaccine for the prevention and treatment of HPV and/or an HPV -induced cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161577811P | 2011-12-20 | 2011-12-20 | |
US61/577,811 | 2011-12-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013093629A2 WO2013093629A2 (en) | 2013-06-27 |
WO2013093629A3 true WO2013093629A3 (en) | 2014-01-16 |
Family
ID=48014103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2012/003006 WO2013093629A2 (en) | 2011-12-20 | 2012-12-19 | Modular vaccines, methods and compositions related thereto |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013093629A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2955250A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002012281A2 (en) * | 2000-08-03 | 2002-02-14 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
EP0138854B1 (en) | 1983-03-08 | 1992-11-04 | Chiron Mimotopes Pty. Ltd. | Antigenically active amino acid sequences |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
IL84154A0 (en) | 1986-10-16 | 1988-03-31 | Microgenesys Inc | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
IL86724A (en) | 1987-06-19 | 1995-01-24 | Siska Diagnostics Inc | Method and kits for the amplification and detection of nucleic acid sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
ATE92538T1 (en) | 1988-01-21 | 1993-08-15 | Genentech Inc | AMPLIFICATION AND DETECTION OF NUCLEIC ACID SEQUENCES. |
CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
EP0386185A1 (en) | 1988-07-29 | 1990-09-12 | IntraCel Corporation | Method for the genetic expression of heterologous proteins by cells transfected in vivo |
CA2003300A1 (en) | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5552143A (en) | 1989-03-24 | 1996-09-03 | The Wistar Institute Of Anatomy & Biology | Recombinant cytomegalovirus vaccine |
US5591439A (en) | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
GB9001766D0 (en) | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
AU672359B2 (en) | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5997878A (en) | 1991-03-07 | 1999-12-07 | Connaught Laboratories | Recombinant poxvirus-cytomegalovirus, compositions and uses |
US5169766A (en) | 1991-06-14 | 1992-12-08 | Life Technologies, Inc. | Amplification of nucleic acid molecules |
US5650398A (en) | 1992-07-02 | 1997-07-22 | Cambridge Biotech Corporation | Drug delivery enhancement via modified saponins |
US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
US6485729B1 (en) | 1993-09-13 | 2002-11-26 | Protein Sciences Corporation | Neuraminidase-supplemented compositions |
US6472374B1 (en) | 1994-12-24 | 2002-10-29 | Cambridge University Technical Services Limited | Endometrial function |
FR2728795B1 (en) | 1994-12-30 | 1997-03-21 | Rhone Merieux | AVIAN RECOMBINANT LIVING VACCINE USING AVIAN HERPES VIRUS AS A VECTOR |
FR2741806B1 (en) | 1995-11-30 | 1998-02-20 | Rhone Merieux | RECOMBINANT LIVING VACCINE BASED ON TYPE 1 FELINE HERPESVIRUS, PARTICULARLY AGAINST FELIN INFECTIOUS PERITONITIS |
FR2750865B1 (en) | 1996-06-27 | 1998-12-04 | Rhone Merieux | RECOMBINANT LIVING VACCINE BASED ON CANINE HERPESVIRUS, IN PARTICULAR FOR SQUARE DISEASE, RABIES OR TYPE 2 PARAINFLUENZA VIRUS |
FR2750866B1 (en) | 1996-06-27 | 1998-11-27 | Rhone Merieux | AVIAN RECOMBINANT LIVING VACCINE USING AVIAN INFECTIOUS LARYNGOTRACHEITIS VIRUS |
US6090393A (en) | 1996-07-03 | 2000-07-18 | Merial | Recombinant canine adenoviruses, method for making and uses thereof |
FR2751223B1 (en) | 1996-07-19 | 1998-12-04 | Rhone Merieux | FELIN POLYNUCLEOTIDE VACCINE FORMULA |
FR2751228B1 (en) | 1996-07-19 | 1998-11-20 | Rhone Merieux | BOVINE POLYNUCLEOTIDE VACCINE FOR INTRADERMAL ROUTE |
FR2751226B1 (en) | 1996-07-19 | 1998-11-27 | Rhone Merieux | POLYNUCLEOTIDE VACCINE FORMULA AGAINST HORSE PATHOLOGIES |
FR2751225B1 (en) | 1996-07-19 | 1998-11-27 | Rhone Merieux | AVIAN POLYNUCLEOTIDE VACCINE FORMULA |
FR2751227B1 (en) | 1996-07-19 | 1998-11-27 | Rhone Merieux | POLYNUCLEOTIDE VACCINE FORMULA AGAINST CANINE CONDITIONS, ESPECIALLY RESPIRATORY AND DIGESTIVE CONDITIONS |
FR2751224B1 (en) | 1996-07-19 | 1998-11-20 | Rhone Merieux | POLYNUCLEOTIDE VACCINE FORMULA AGAINST BREATHING AND PIG REPRODUCTIVE CONDITIONS |
FR2751229B1 (en) | 1996-07-19 | 1998-11-27 | Rhone Merieux | POLYNUCLEOTIDE VACCINE FORMULA IN PARTICULAR AGAINST RESPIRATORY PATHOLOGY OF CATTLE |
ES2153654T3 (en) | 1996-10-17 | 2001-03-01 | Oxford Biomedica Ltd | RETROVIRAL VECTORS. |
US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
FR2757061B1 (en) | 1996-12-16 | 1999-03-26 | Rhone Merieux | AVIAN RECOMBINANT LIVING VACCINE USING AVIAN INFECTIOUS LARYNGOTRACHEITIS VIRUS AS A VECTOR |
FR2758986B1 (en) | 1997-01-31 | 1999-04-30 | Rhone Merieux | AVIAN RECOMBINANT LIVING VACCINE USING AVIAN INFECTIOUS LARYNGOTRACHEITIS VIRUS AS A VECTOR |
US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
US6368603B1 (en) | 1997-03-05 | 2002-04-09 | Merial Limited | Lyme combination compositions and uses |
US5990091A (en) | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
US20020136722A1 (en) | 1997-06-18 | 2002-09-26 | Heath Andrew William | Vaccination method |
US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
CA2654522C (en) | 1997-08-29 | 2014-01-28 | Antigenics Inc. | Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient |
FR2781159B1 (en) | 1998-07-06 | 2000-10-06 | Merial Sas | CIRCOVIRUS VACCINE AND PIG PARVOVIRUS |
US6391314B1 (en) | 1997-10-03 | 2002-05-21 | Merial | Porcine circoviruses vaccines diagnostic reagents |
US6224882B1 (en) | 1997-11-07 | 2001-05-01 | Protein Science Corp. | Insect cells or fractions as adjuvant for antigens |
PT1895010E (en) | 1997-12-22 | 2012-01-25 | Oxford Biomedica Ltd | Equine infectious anaemia virus (eiav) based vectors |
US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
AU6845201A (en) | 2000-06-15 | 2001-12-24 | Us Gov Health & Human Serv | A recombinant non-replicating virus expressing GM-CSF and uses thereof to enhance immune responses |
-
2012
- 2012-12-19 WO PCT/IB2012/003006 patent/WO2013093629A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002012281A2 (en) * | 2000-08-03 | 2002-02-14 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
Non-Patent Citations (9)
Title |
---|
BRULET JEAN-MARC ET AL: "DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection.", EUROPEAN JOURNAL OF IMMUNOLOGY FEB 2007, vol. 37, no. 2, February 2007 (2007-02-01), pages 376 - 384, XP002714217, ISSN: 0014-2980 * |
CHENG WEN-FANG ET AL: "Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 108, no. 5, 1 September 2001 (2001-09-01), pages 669 - 678, XP002479997, ISSN: 0021-9738 * |
FREIGANG STEFAN ET AL: "A lymphocytic choriomeningitis virus glycoprotein variant that is retained in the endoplasmic reticulum efficiently cross-primes CD8(+) T cell responses.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 14 AUG 2007, vol. 104, no. 33, 14 August 2007 (2007-08-14), pages 13426 - 13431, XP002714214, ISSN: 0027-8424 * |
JI HONGXIU ET AL: "Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors", HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 10, no. 17, 20 November 1999 (1999-11-20), pages 2727 - 2740, XP002956558, ISSN: 1043-0342, DOI: 10.1089/10430349950016474 * |
KOEN OOSTERHUIS ET AL: "Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7", INTERNATIONAL JOURNAL OF CANCER, vol. 129, no. 2, 15 July 2011 (2011-07-15), pages 397 - 406, XP055031276, ISSN: 0020-7136, DOI: 10.1002/ijc.25894 * |
OOSTERHUIS KOEN ET AL: "Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.", HUMAN GENE THERAPY DEC 2012, vol. 23, no. 12, December 2012 (2012-12-01), pages 1301 - 1312, XP002714216, ISSN: 1557-7422 * |
RIVERA V M ET AL: "Regulation of protein secretion through controlled aggregation in the endoplasmic reticulum.", SCIENCE (NEW YORK, N.Y.) 4 FEB 2000, vol. 287, no. 5454, 4 February 2000 (2000-02-04), pages 826 - 830, XP002714215, ISSN: 0036-8075 * |
STEVENSON FREDA K ET AL: "DNA fusion gene vaccines against cancer: from the laboratory to the clinic.", IMMUNOLOGICAL REVIEWS JUN 2004, vol. 199, June 2004 (2004-06-01), pages 156 - 180, XP002714213, ISSN: 0105-2896 * |
WU A ET AL: "Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer.", GENE THERAPY MAR 2011, vol. 18, no. 3, March 2011 (2011-03-01), pages 304 - 312, XP002714212, ISSN: 1476-5462 * |
Also Published As
Publication number | Publication date |
---|---|
WO2013093629A2 (en) | 2013-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013004817A (en) | Inflammatory disease. | |
WO2015138357A3 (en) | Compositions useful in treatment of otc deficency | |
WO2013130703A3 (en) | Inhibitors of hepatitis b virus covalently closed circular dna formation and their method of use | |
WO2012047856A3 (en) | Novel inhibitors of secretion of hepatitis b virus antigens | |
EA201590343A1 (en) | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | |
GB201118656D0 (en) | New compounds | |
MY166557A (en) | Quinazoline derivatives for the treatment of viral infections and further diseases | |
PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
MX349004B (en) | New compounds. | |
WO2013098655A9 (en) | Vaccines directed against human enteroviruses | |
MX2012013731A (en) | Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules. | |
MX347734B (en) | S100a4 antibodies and therapeutic uses thereof. | |
WO2011086093A3 (en) | Pharmaceutical compositions for oral administration of insulin peptides | |
MX2013013801A (en) | Immunostimulatory oligodeoxynucleotides. | |
WO2009009759A3 (en) | Yersinia pestis antigens, vaccine compositions, and related methods | |
NZ708016A (en) | Lyophilized preparations of melphalan flufenamide | |
IN2014DN03054A (en) | ||
WO2012119070A3 (en) | Silicone-based ophthalmic formulations | |
WO2009135199A3 (en) | Vaccine compositions and methods | |
MX2013003245A (en) | Bvdv vaccine. | |
WO2014140166A3 (en) | Vaccine | |
EP2785335B8 (en) | Methods and pharmaceutical compositions for the treatment of darier disease | |
TN2012000217A1 (en) | The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease | |
WO2011058245A8 (en) | Novel mannopyranoside derivatives with anticancer activity | |
WO2013093629A3 (en) | Modular vaccines, methods and compositions related thereto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12837640 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12837640 Country of ref document: EP Kind code of ref document: A2 |